血浆激肽释放酶与炎症研究进展

Plasma kallikrein in inflammation

血浆激肽释放酶(pKal)是血浆激肽释放酶-激肽系统(KKS)的重要组分,其通过KKS、补体系统、肾素-血管紧张素系统(RAS)参与炎症反应,与遗传性血管性水肿(HAE)、类风湿性关节炎(RA)、新型冠状病毒肺炎(COVID-19)等疾病的炎性发生发展密切相关,是HAE、RA等炎症性疾病防治靶点,也可能作为防治COVID-19的新途径。

As an important component of kallikrein-kinin system(KKS),plasma kallikrein(pKal)is involved in inflammation process via KKS,complement system and renin-angiotensin system(RAS)and plays an important role in angioedema(HAE),rheumatoid arthritis(RA)and corona virus disease 2019(COVID-19).pKal maybe a therapeutic target against inflammatory diseases,and pKal inhibitors are being researched and developed for the prevention and treatment of inflammatory diseases such as HAE and RA,and may also be new agents for the prevention and treatment of COVID-19.